Title page:

The epidemiologic parameters for COVID-19: A Systematic Review and Meta-Analysis

Type: Systematic Review and Meta-Analysis

Author's name:

Neda Izadi, Niloufar Taherpour, Yaser Mokhayeri, Sahar Sotoodeh Ghorbani, Khaled Rahmani, Seyed Saeed Hashemi Nazari *

Author's details

Neda Izadi

Ph.D Student, Student Research Committee, Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: neda.izady@yahoo.com ORCID: 0000-0002-6373-1113

Niloufar Taherpour

Department of Epidemiology, school of public health and safety, Shahid beheshti University of medical sciences, Tehran, Iran. E-mail: Taherpour.n@gmail.com ORCID: 0000-0002-8336-0671

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Yaser Mokhayeri

Department of Epidemiology and Biostatistics, school of health and nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran. E-mail: yasermokhayeri@yahoo.com ORCID: 0000-0002-4843-8218

Sahar Sotoodeh Ghorbani

Department of Epidemiology, school of public health and safety, Shahid beheshti University of medical sciences, Tehran, Iran. E-mail: saharsotoodeh2@gmail.com ORCID: 0000-0001-8207-1352

Khaled Rahmani

Assistant professor of epidemiology, liver and digestive research center, research institute for health development, kurdistan university of medical sciences, Sanandaj, Iran. E-mail: Khaledrahmani111@yahoo.com ORCID: 0000-0002-0860-8040

Seyed Saeed Hashemi Nazari * (Corresponding author)

Associate Professor, Safety Promotion and Injury Prevention Research Center, Department of Epidemiology, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: saedh_1999@yahoo.com ORCID: 0000-0002-0883-3408
Tel: +98 (21) 22431993
Fax: +98 (21) 22 43 97 84

The epidemiologic parameters for COVID-19: A Systematic Review and Meta-Analysis
**Introduction:** The World Health Organization (WHO) declared the outbreak to be a public health emergency and international concern and recognized it as a pandemic. The aim of this study was to estimate the epidemiologic parameters of novel coronavirus (COVID-19) pandemic for clinical and epidemiological help.

**Methods:** Four electronic databases including Web of Science, Medline (PubMed), Scopus and Google Scholar were searched for literature published from early December 2019 up to 23 March 2020. The "metan" command was used to perform a fixed or random effects analysis. Cumulative meta-analysis was performed using the "metacum" command.

**Results:** Totally 76 observational studies were included in the analysis. The pooled estimate for $R_0$ was 2.99 (95% CI: 2.71-3.27) for COVID-19. The overall $R_0$ was 3.23, 1.19, 3.6 and 2.35 for China, Singapore, Iran and Japan, respectively. The overall Serial Interval, doubling time, incubation period were 4.45, 4.14 and 4.24 days for COVID-19. In addition, the overall estimation for growth rate and case fatality rate for COVID-19 were 0.38% and 3.29%, respectively.

**Conclusion:** Calculating the pooled estimate of the epidemiological parameters of COVID-19 as an emerging disease, could reveal epidemiological features of the disease that consequently pave the way for health policy makers to think more about control strategies.

**Keywords:** Epidemiologic Parameters; $R_0$; Serial Interval; Doubling Time; Case Fatality Rate; COVID-19
Introduction

Coronaviruses are a group of RNA viruses that cause diseases among humans and animals (1). The latest of coronavirus types as a novel coronavirus that was named severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) or COVID-19 occurred in Wuhan, China in December 2019 with a human outbreak (2).

The World Health Organization (WHO) declared the outbreak to be a public health emergency and international concern and recognized it as a pandemic on 11 March 2020 (3). COVID-19 has widely spread in the world and is prevalent in different countries such as China, Italy, United states, France, Spain, Iran and Germany with 2,833,697 cases and 197,354 deaths and 807,469 recovered until 24 April in the whole world (4). The main rout of transmission of COVID-19 is based on human-to-human transmission via either respiratory droplets, saliva or close contacts with infected people or aerosol generation procedures during clinical care of COVID-19 patients (5).

Most COVID-19 infected people (80.9%) are with mild to moderate respiratory syndromes, old people or patients with underlying diseases such as diabetes, cardiovascular disease, cancer, immune deficiency and respiratory disease are more at risk to develop severe (13.8%) and critical (4.7%) disease (6,7).

Knowledge regarding epidemiological characteristics and parameters of the infectious diseases such as, incubation period (time from exposure to the agent until the first symptoms develop), serial interval (duration between symptom onset of a primary case and symptom onset of its secondary cases), basic reproduction number (R₀) (the transmission potential of a disease) and other epidemiologic parameters is important for modelling and estimation of epidemic trends and also implementation and evaluation of preventive procedures (8-11).
About COVID-19 pandemic parameters, there are many reports from different countries in the world. For example, about 25.6 % to 51.7% of patients have been reported to be asymptomatic or with mild symptoms (12) and 25-30% of them have been admitted to ICU for medical care (13). Case-fatality rate was reported in China and other countries among old patients 6% (4-11% ranges) and 2.3 % in all ages (13,14). Furthermore, the median incubation period was reported as 5-6 days (2-14 ranges) from WHO while, in China incubation period was reported up to 24 days (15,16). Also, according to the different mathematical models, $R_0$ was reported about 6.47 (1.66-10 ranges) in China, 2.6 in South-Korea and 4.7 in Iran (17,18,19).

Thus, according to the reports from different countries about epidemiological characteristics of COVID-19 pandemic, different methods and different values of parameters have been observed. So, for efficient estimation and forecasting of disease spreading, we need acceptable and real values of each parameter. The present study was conducted to provide a systematic assessment and estimation of parameters related to COVID-19. This evaluation will help researchers with better prediction and estimation of current epidemic trends.

**Method**

The current study is a systematic review and meta-analysis to determine the epidemiologic parameters for COVID-19.

**Search Strategy**

To find relevant studies, a comprehensive literature search of the Web of Science, Medline (Pubmed), Scopus and Google Scholar was performed for observational studies published electronically from early December 2019 up to 23 March 2020.

Two researchers independently searched studies. In search strategy, English keywords and probable combination of them were used. The keywords included "novel coronavirus" and "2019-
noCov" • "COVID-19" • "basic reproduction number" • "serial interval" • "incubation period" • "doubling time" • "growth rate" • "case-fatality rate" • "mortality rate" • "onset of symptom to hospitalization". The Boolean operators (‘OR ‘and ‘AND’) were used for combination of keywords. The search strategy was as follows:

**Keywords:** (novel coronavirus OR 2019-nCov OR COVID-19) AND (basic reproduction number OR basic reproductive rate) OR (case fatality rate OR case fatality ratio) OR mortality rate OR doubling time OR growth rate OR incubation period OR onset of symptom to hospitalization.

**Study Selection**

Consistent with PRISMA guidelines, the standard meta-analysis techniques, we included studies. All of the extracted articles independently were screened by two researchers. Abstract and full text of the articles were reviewed and duplicated studies were excluded and then relevant articles were selected for data extraction.

**Study inclusion and exclusion criteria**

All epidemiological studies designs (observational studies) including peer reviewed or not peer reviewed articles that provided the epidemiologic parameters of interest regarding the novel corona virus were included. In addition, irrelevant studies, letters and news and studies that didn’t report epidemiologic parameters were excluded.

**Screening and Data extraction**

All articles were reviewed independently by four researchers and information was extracted using designed checklist (Appendix 1). Extracted items were name of the first author, years and month of article published, duration of the study, location of study conduction, type of
parameters, point estimate or mean/median and its confidence interval for epidemiological parameters and review status of articles (peer-reviewed or not).

**Quality assessment of studies**

To assess the quality of included the peer-reviewed and not peer reviewed articles, we used the STROBE quality assessment scale for observational studies. We assessed the quality of all studies and finally, studies with high and medium quality were included in the analyses.

**Statistical analysis**

The “metan” command was used to apply a fixed or random effects model based on Cochran’s Q-test results or a large Higgins and Thompson’s I² value. Forest plots were used for graphical description of the results. Also, the “metacum” command was used for cumulative meta-analysis to determine trend of basic reproductive number (R₀).

In studies that mortality rate was reported, because of the denominator was confirmed cases, it was considered a case fatality rate (CFR). In addition, for studies that reported the median and interquartile range (IQR), the median was considered equivalent to the mean and the IQR was converted to standard deviation using the “IQR/1.35” formula. Stata 14 was used for all statistical analyses.

**Results**

Having assessed the quality of relevant studies, 76 observational studies up to 23 March, 2020 were included in this study (Follow diagram). The majority of studies were done in Wuhan, China. Detailed information of the eligible studies and their characteristics has been shown in Appendix 1 (12,17,18,20-92).

- **The overall basic reproductive number (R₀) by country and peer review status**

  **Total:** The overall R₀ was 2.99 (95% CI: 2.71-3.27) for COVID-19 (Table 1).
**Country:** The overall $R_0$ was 3.23, 1.19, 3.6 and 2.35 for China, Singapore, Iran and Japan, respectively (Table 1).

**Peer review status:** The overall $R_0$ was 2.75 and 3.08 for peer reviewed and not peer reviewed articles, respectively (Table 1).

- **The overall serial interval (SI) by country and peer review status**

  **Total:** The overall SI was 4.45 days (95% CI: 4.03-4.87) for COVID-19.

  **Country:** Using random effect model, the overall SI was 4.46 and 4.64 days for China and Singapore, respectively (Error! Reference source not found.).

  **Peer review status:** The overall SI was 5.3 and 4.39 days for peer reviewed and not peer reviewed articles, respectively (Error! Reference source not found.2).

- **The overall doubling time by peer review status**

  **Total:** The overall doubling time was 4.14 days (95% CI: 2.67-5.62) for COVID-19.

  **Peer review status:** The overall doubling time was 3.33 and 4.64 days for peer reviewed and not peer reviewed articles, respectively (Error! Reference source not found.3).

- **The overall incubation period by peer review status**

  **Total:** The overall incubation period was 4.24 days (95% CI: 3.03-5.44) for COVID-19.

  **Peer review status:** The overall incubation period was 4.03 and 5.82 days for peer reviewed and not peer reviewed articles, respectively (Table 1).

- **The overall estimation for other epidemiologic parameters**

  The overall estimation for growth rate and case fatality rate for COVID-19 were 0.38% and 3.29%, respectively (Table 1 & Fig 4). In addition, the overall time from symptom onset to hospitalization was 5.09 days for COVID-19 (Table 1).
- The trend of $R_0$ for COVID-19

Based on the cumulative meta-analysis, the trend of $R_0$ had been increasing at first and, then, decreasing in March.

Flow diagram of the study selection process and including publications for the epidemiologic parameters for COVID-19
Table 1. The overall estimation of epidemiologic parameters for COVID-19

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. of studies</th>
<th>Estimate</th>
<th>95% CI</th>
<th>P for Heterogeneity</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic Reproductive Number (R₀)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>69</td>
<td>2.99</td>
<td>2.71-3.27</td>
<td>&lt;0.001</td>
<td>99.3</td>
</tr>
<tr>
<td>Korea</td>
<td>1</td>
<td>2.6</td>
<td>2.5-2.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>China</td>
<td>57</td>
<td>3.23</td>
<td>2.92-3.55</td>
<td>&lt;0.001</td>
<td>99.1</td>
</tr>
<tr>
<td>Singapore</td>
<td>6</td>
<td>1.19</td>
<td>1.07-1.3</td>
<td>&lt;0.001</td>
<td>82.2</td>
</tr>
<tr>
<td>Iran</td>
<td>2</td>
<td>3.6ᵃ</td>
<td>3.1-4.09</td>
<td>0.99</td>
<td>-</td>
</tr>
<tr>
<td>Japan</td>
<td>3</td>
<td>2.35</td>
<td>2.1-2.6</td>
<td>0.007</td>
<td>80.1</td>
</tr>
<tr>
<td>Peer Review</td>
<td>13</td>
<td>2.75</td>
<td>2.25-3.24</td>
<td>&lt;0.001</td>
<td>99.4</td>
</tr>
<tr>
<td>Not Peer Review</td>
<td>56</td>
<td>3.08</td>
<td>2.73-3.43</td>
<td>&lt;0.001</td>
<td>99.3</td>
</tr>
<tr>
<td><strong>Growth Rate (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>5</td>
<td>0.38</td>
<td>0.2-0.55</td>
<td>&lt;0.001</td>
<td>97.7</td>
</tr>
<tr>
<td><strong>Symptom onset to Hospitalization (day)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>6</td>
<td>5.09</td>
<td>2.15-8.02</td>
<td>0.03</td>
<td>53</td>
</tr>
<tr>
<td><strong>Incubation Period (day)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>22</td>
<td>4.24</td>
<td>3.03-5.44</td>
<td>0.02</td>
<td>35</td>
</tr>
<tr>
<td>Peer Review</td>
<td>18</td>
<td>4.03</td>
<td>2.72-5.33</td>
<td>0.01</td>
<td>41</td>
</tr>
<tr>
<td>Not Peer Review</td>
<td>4</td>
<td>5.82ᵃ</td>
<td>2.91-8.74</td>
<td>0.76</td>
<td>16</td>
</tr>
</tbody>
</table>

ᵃ Fixed effect model

**Discussion**

In this secondary analysis, we aimed to calculate the pooled estimate of some epidemiological parameters of COVID-19 namely basic reproductive number (R₀), serial interval, doubling time, incubation period, growth rate, case fatality rate (CFR), and time from symptom onset to hospitalization. Overall, the estimates were 2.99, 4.45 days, 4.14 days, 4.24 days, 0.38%, 3.29%, and 5.09 days, in the same order. Considering urgent issues in pandemic situation, peers have not
reviewed some published papers. Therefore, we tried to calculate the pooled parameters by peer review status.

It should be noted that, \( R_0 \) variations to some extent might be due to different methods calculations including exponential growth method, maximum likelihood, and Bayesian time-dependent method (93-95).

According to our results the pooled estimate of CFR 3.29\% (95\% CI: 2.78-3.81) is lower than SARS-CoV(96) and MERS-CoV (97). Health control policies, medical standard, and detection rate could affect CFR (35). Moreover, CFR estimate in the early phase of the epidemic might be biased (overestimated). Usually in the early phase, some subclinical cases and patients with mild symptoms may not be detected (detection bias) (98,99).

Pooled estimate of incubation period using 22 studies was 4.24 days (95\% CI: 3.03, 5.44). Valid and precise estimate of incubation period has a pivotal role for duration of quarantine (50). In fact, knowledge about incubation period is useful for surveillance and control approaches, also modeling and monitoring activities (100).

Our estimate for overall doubling time- time for a given quantity to double in size or number at a constant growth rate was 4.14 days (95\% CI: 2.67, 5.62). The doubling time has an important implication for predicting epidemic. Generally, social distancing, quarantine, and active surveillance are needed to reduce transmission and consequently extend the doubling time (101). Moreover, the authors tried to estimate pooled measures for growth rate and serial interval. These two epidemiological parameters are used to estimate reproduction number (102).

As a limitation, all 76 studies (except for one, Mirjam E Kretzschmar et al) (103) have been conducted in Asia, particularly in Wuhan, China. Some epidemiological parameters in Europe, Africa, and America could be different based on control strategies. Hence, distribution of these
epidemiological parameters could be more globally. Future studies to calculate more generalized pooled estimates, using studies all over the world, would be recommended.

**Conclusions**

Calculating the pooled estimate of the epidemiological parameters of COVID-19 as an emerging disease, could reveal epidemiological features of the disease that consequently pave the way for health policy makers to think more about control strategies.

**Acknowledgment**

We would like to appreciate all those researchers who helped us to conduct this study.

**Funding**

This study was supported by School of Public Health and Safety, Shahid Beheshti University of Medical Sciences grant number 23149. The funding agency did not play any role in the planning, conduct, and reporting or in the decision to submit the paper for publication.

**Competing interests**

The authors declare that they have no competing interests.
References


Figure 1. The overall serial interval (SI) for COVID-19 by country

<table>
<thead>
<tr>
<th>Study ID</th>
<th>ES (95% CI)</th>
<th>% Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qun Li (2020)</td>
<td>7.50 (5.30, 19.00)</td>
<td>0.37</td>
</tr>
<tr>
<td>Chong You (2020)</td>
<td>4.41 (4.32, 4.49)</td>
<td>26.49</td>
</tr>
<tr>
<td>Lauren C. Tindale (2020)</td>
<td>4.22 (3.43, 5.01)</td>
<td>13.72</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>4.02 (0.00, 13.45)</td>
<td>0.38</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>2.90 (0.00, 13.47)</td>
<td>0.38</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>3.95 (0.00, 12.73)</td>
<td>0.43</td>
</tr>
<tr>
<td>Hiroshi Nishiura (2020)</td>
<td>4.60 (3.50, 5.90)</td>
<td>8.38</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>3.95 (0.00, 12.51)</td>
<td>0.44</td>
</tr>
<tr>
<td>Joseph T WU (2020)</td>
<td>7.00 (5.80, 8.10)</td>
<td>8.87</td>
</tr>
<tr>
<td>Hiroshi Nishiura (2020)</td>
<td>4.00 (3.10, 4.90)</td>
<td>11.98</td>
</tr>
<tr>
<td>Jiaqiang Liao (2020)</td>
<td>1.90 (0.40, 6.20)</td>
<td>1.94</td>
</tr>
<tr>
<td>Zhanwei Du (2020)</td>
<td>3.96 (3.53, 4.39)</td>
<td>20.89</td>
</tr>
<tr>
<td>Subtotal (I-squared = 61.6%, p = 0.003)</td>
<td>4.46 (3.97, 4.94)</td>
<td>94.26</td>
</tr>
<tr>
<td>Singapore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>5.21 (0.00, 13.94)</td>
<td>0.36</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>5.29 (0.00, 13.16)</td>
<td>0.40</td>
</tr>
<tr>
<td>Lauren C. Tindale (2020)</td>
<td>4.56 (2.69, 6.42)</td>
<td>4.25</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>3.86 (0.00, 13.88)</td>
<td>0.36</td>
</tr>
<tr>
<td>Ganyani Tapiwa (2020)</td>
<td>5.19 (0.00, 13.45)</td>
<td>0.38</td>
</tr>
<tr>
<td>Subtotal (I-squared = 0.0%, p = 0.998)</td>
<td>4.64 (3.00, 6.27)</td>
<td>5.74</td>
</tr>
<tr>
<td>Overall (I-squared = 44.6%, p = 0.025)</td>
<td>4.45 (4.03, 4.87)</td>
<td>100.00</td>
</tr>
</tbody>
</table>

NOTE: Weights are from random effects analysis.
Figure 2. The overall serial interval (SI) for COVID-19 by peer review status
Figure 3. The overall doubling time for COVID-19 by peer review status

Figure 4. The overall case fatality rate (CRF) for COVID-19